Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain
Executive Summary
The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.
You may also be interested in...
AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker
Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.
Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results
Larger of two doses of the NGF inhibitor hit two efficacy endpoints, but the rate of joint health outcomes on a composite measure was higher than control by a statistically significant margin.
Tanezumab Dances Through Back Pain Studies With “Acceptable” Safety Answers
In its latest TANGO trial for chronic lower back pain, Eli Lilly and Pfizer’s tanezumab has shown efficacy at 10 mg, but its 5 mg dose missed the statistically significant mark. Vitally, analysts are encouraged by safety data.